COMPASS Pathways

Q: Where is COMPASS Pathways headquartered?

COMPASS Pathways is headquartered in London, United Kingdom.

Q: How many employees does COMPASS Pathways have?

COMPASS Pathways has about 51 employees.

Q: Has COMPASS Pathways raised funding?

Yes. Fundz has recorded 1 funding event for COMPASS Pathways. The most recent, Funding Round of Undisclosed, was in Aug 2023.

Q: Who leads COMPASS Pathways?

Mary-Rose Hughes is a Vice President Of Finance At Compass at COMPASS Pathways.

Q: What is the latest news on COMPASS Pathways?

On Sep 30, 2026, Compass Pathways Appoints Kelley Boucher as Chief People Officer

Q: Is COMPASS Pathways a public company?

Yes. COMPASS Pathways is publicly traded under the ticker CMPS.

London, United Kingdom · Biotechnology, Health Care

Compass Pathways plc is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is focused on improving the lives of those who are living with mental health challenges.

Key facts

Headquarters: London, United Kingdom
Employees: 51
Industries: Biotechnology, Health Care
Status: Public (CMPS)
Website: compasspathways.com
LinkedIn: Company page

Recent activity at COMPASS Pathways

Sep 30, 2026: Compass Pathways Appoints Kelley Boucher as Chief People Officer
Jul 07, 2026: SEC 8-K (7.01): On July 7, 2026, Compass Pathways plc conducted an investor presentation aimed at providing key updates and insights to its stakeholders. The presentation includes detailed information regarding the company's strategic initiatives, recent developments, and financial outlook for the upcoming quarters. This event is significant as it allows the company to engage directly with investors and communicate its vision, which can impact shareholder confidence. A copy of the presentation has been attached as Exhibit 99.1 to the filing.
Jul 07, 2026: SEC 8-K (8.01): On July 7, 2026, the Company reported significant results from its ongoing Phase 3 COMP006 trial of COMP360, a proprietary formulation of psilocybin for treating treatment-resistant depression (TRD). The study results show that 39% of participants in the 25 mg treatment group achieved a meaningful reduction in depression scores by week 6, sustaining this benefit through week 26. This builds on earlier findings from the COMP005 trial. With a rolling New Drug Application in progress, the Company anticipates launching COMP360 in early 2027, subject to FDA approval. This announcement represents a major step in the evaluation of COMP360's efficacy and potential market introduction, indicating its role in addressing severe TRD, which affects a highly chronic patient population.
Feb 19, 2026: SEC 8-K (1.01): On February 18, 2026, Compass Pathways plc entered into an Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, Cantor Fitzgerald & Co., and Stifel, Nicolaus & Company, Incorporated. This agreement relates to the issuance and sale of 17,500,000 American Depositary Shares (ADSs) at a public offering price of $8.00 per ADS, along with pre-funded warrants for 1,250,000 ADSs at $7.999 each. The expected gross proceeds from this public offering are approximately $150 million, and the closing is anticipated on February 20, 2026, subject to customary closing conditions. Moreover, the Company has provided underwriters a 30-day option to purchase an additional 2,812,500 ADSs. Restrictions on the sale of securities by Company officers and directors for 60 days post-agreement are also included.
Feb 17, 2026: SEC 8-K (8.01): On February 17, 2026, the Company announced the successful achievement of the primary endpoint in the Phase 3 COMP006 trial for COMP360, a synthetic formulation of psilocybin, aimed at treating treatment-resistant depression (TRD). The trial compared two fixed doses of COMP360 (25 mg vs 1 mg) and found a highly statistically significant reduction in MADRS scores, with a p-value of <0.001, leading to a meaningful -3.8 point difference at Week 6. Cumulatively across trials COMP005 and COMP006, COMP360 demonstrated a generally well-tolerated safety profile, suggesting rapid onset of efficacy starting the day after administration. Following these results, the Company is seeking a meeting with the FDA to discuss a possible rolling submission and review.
Jan 09, 2026: Compass Pathways partners with Radial Health to enhance mental health treatment access through clinic network.
Jan 07, 2026: SEC 8-K (1.01): On January 5, 2026, COMPASS Pathways plc and its subsidiaries entered into a Third Amendment to their loan and security agreement with Hercules Capital, Inc. This amendment permits five tranches of term loans totaling up to $150 million, with the first tranche of $50 million funded immediately. The agreement includes various performance milestones for additional tranches and establishes an interest rate of at least 9.75%. Proceeds from this loan will also be used to repay approximately $31.1 million of previous borrowing. The initial principal payments are deferred until 2029, with a maturity date set for January 5, 2031.
Jan 06, 2026: Compass Pathways Forms Partnership with Radial to Enhance Patient Experience for COMP360 Treatment
Oct 29, 2025: SEC 8-K (5.02): On October 26, 2025, COMPASS Pathways plc appointed Dr. Jeff Jonas to its Board of Directors, effective October 29, 2025, designating him as a Class II director. Dr. Jonas, who has extensive experience in the biotechnology sector, will also serve on the audit and risk and scientific committees of the Board. He will receive an option to purchase 52,000 ordinary shares under the Company’s 2020 Share Option and Incentive Plan, with compensation structured according to the Directors’ Remuneration Policy for Non-Executive Directors. This option will vest over three years, contingent on his continued service, reflecting the Company's commitment to attract experienced leadership to enhance strategic governance.
Oct 26, 2025: SEC 8-K (5.02): On October 26, 2025, COMPASS Pathways plc appointed Jeff Jonas, M.D., to its Board of Directors, effective October 29, 2025. Dr. Jonas will serve as a Class II director until the next annual general meeting, when he will be eligible for re-election. In addition to his board duties, he will also participate as a member of the audit and risk committee and the scientific committee. Dr. Jonas has extensive experience in the life sciences sector, having been a partner at Cure Ventures since January, indicating a strategic move to enhance the company's oversight and expertise in scientific matters.